SCHEMBL5136898

SCHEMBL5136898

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccc(F)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
TP53 P04637 2/20 0.38
TSPO P30536 1/20 0.36
SCD O00767 1/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TSHR P16473 2/20 0.36
CNR2 P34972 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.36
CRHR1 P34998 2/20 0.36
GNRHR P30968 2/20 0.35
UBE2M P61081 1/20 0.35
DCUN1D1 Q96GG9 1/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648503 0.93 C5AR1 (0.47) C5AR1ALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL5136217 0.92 C5AR1 (0.45) C5AR1TP53ALDH1A1KDM4ELMNA
SCHEMBL5135905 0.92 C5AR1 (0.45) C5AR1TP53TSPOALDH1A1KDM4E
SCHEMBL649882 0.91 C5AR1 (0.41) C5AR1ALDH1A1LMNAHTTTSHR
SCHEMBL5137368 0.90 TP53 (0.46) C5AR1TP53ALDH1A1KDM4ELMNA
SCHEMBL5136200 0.90 C5AR1 (0.43) C5AR1TP53ALDH1A1KDM4ELMNA
SCHEMBL651365 0.89 C5AR1 (0.46) C5AR1TP53ALDH1A1KDM4ELMNA
SCHEMBL5136054 0.89 C5AR1 (0.42) C5AR1TSPOSCDALDH1A1KDM4E
SCHEMBL5170483 0.89 C5AR1 (0.45) C5AR1TP53ALDH1A1KDM4ELMNA
SCHEMBL648035 0.89 C5AR1 (0.46) C5AR1ALDH1A1KDM4ETSHRCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed